Academic Profile

Academic Profile

Assoc Prof Hannes Hentze

Adjunct Associate Professor

Assoc Prof Hannes Hentze

Adjunct Assoc. Prof. Hannes Hentze is a pharmacologist with international work experience in academic research, small biotech companies, and in the pharmaceutical industry. He is currently active as an independent consultant, with ASLAN Pharmaceuticals as the main client. His expertise includes preclinical oncology, diabetes, and cardiovascular disease, as well as animal models for cell therapy applications. He has published >35 peer-reviewed articles, reviews and book chapters in the areas of liver disease, redox regulation, stem cell therapy, diabetes and oncology (H factor: 27).


Since 2018 Independent Consultant, Vivology Consulting, Singapore
2014 - 2018 Director, Study Services, BRC, A*STAR Singapore
2009 - 2013 Study Director/Principal Scientist, Translational Medicine Research Centre (TMRC), MSD Singapore
2007 - 2009 Senior Research Scientist, Biology Department, S*BIO Pte Ltd, Singapore
2004 - 2007 Senior Research Scientist, ES Cell International Pte Ltd, Singapore
2001 - 2004 Postdoctoral Fellow, Institute of Molecular and Cell Biology (IMCB), Singapore


2018 - 2019: Executive MBA, INSEAD
1998 - 2000 PhD Degree Biology, Department of Biochemical Pharmacology, University of Konstanz, Germany, thesis: “Regulation of death receptor-mediated cell demise by glutathione” (
1992 - 1997 Master’s Degree Biology (Diploma), Department of Biochemical Pharmacology, University of Konstanz, Germany
1991 - 1992 Study of Music (Herrmann-Zilcher-Konservatorium Würzburg)


Chia S, Low JL, Zhang X, Kwang XL, Chong FT, Sharma A, Bertrand D, Toh SY, Leong HS, Thangavelu MT, Hwang JSG, Lim KH, Shanthakumar T, Tan HK, Su Y, Hui Choo S, Hentze H, Tan IBH, Lezhava A, Tan P, Tan DSW, Periyasamy G, Koh JLY, Gopalakrishna Iyer N, DasGupta R (2017) Phenotype-driven Precision Oncology as a guide for clinical decisions one patient at a time. Nat Commun 8(1):435

Chu X, Shih SJ, Shaw R, Hentze H, Chan GH, Owens K, Wang S, Cai X, Newton D, Castro-Perez J, Salituro G, Palamanda J, Fernandis A, New LS, Liaw A, Savage M, Evers R (2015) Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans. Drug Metab Dispos, 43(6):851-863)

Rajendran R, Wei H, Tang MY, Liang JM, Choo S, Reese T, Hentze H, Boxtel S, Cliffe A, Rogers K, Henry B, Chuang KH (2014). Early detection of anti-angiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRI. Cancer Med, 3(1):47-60

Hentze H, Jensen KK, Chia SM, Johns DG, Shaw RJ, Davis HR Jr, Shih SJ, Wong KK (2013). Inverse relationship between LDL cholesterol and PCSK9 plasma levels in dyslipidemic cynomolgus monkeys: effects of LDL lowering by ezetimibe in the absence of statins. Atherosclerosis 231(1):84-90

Novotny-Diermayr V, Hart S, Goh KC, Cheong A, Ong LC, Hentze H, Pasha MK, Jayaraman R, Ethirajulu K, Wood JM (2012) The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J 2(5): e69

Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, William A, Lee A, Poulsen A, Jayaraman R, Ong KH, Ethirajulu K, Dymock B, Wood J (2011) SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 25(11): 1751-1759

Hentze H, Soong PL, Wang ST, Putti T, Phillips B, Dunn R (2009) Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies. Stem Cell Res 2(3): 198-210

Research Interests
I do not have an active research program at NTU as an Adjunct Associate Professor.

« Back to Category Write-up